Cargando…
An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo
The design of targeted platinum(iv) prodrugs is a very promising approach to enhance the low selectivity of platinum(ii) drugs towards cancerous tissue in order to reduce the impact on healthy tissue and, consequently, the often severe side-effects. Herein, we report a set of mono-functionalized cis...
Autores principales: | Mayr, Josef, Heffeter, Petra, Groza, Diana, Galvez, Luis, Koellensperger, Gunda, Roller, Alexander, Alte, Beatrix, Haider, Melanie, Berger, Walter, Kowol, Christian R., Keppler, Bernhard K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Royal Society of Chemistry
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409245/ https://www.ncbi.nlm.nih.gov/pubmed/28507680 http://dx.doi.org/10.1039/c6sc03862j |
Ejemplares similares
-
Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo
por: Schueffl, Hemma, et al.
Publicado: (2021) -
Human serum albumin as a copper source for anticancer thiosemicarbazones
por: Schaier, Martin, et al.
Publicado: (2023) -
Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
por: Kastner, Alexander, et al.
Publicado: (2023) -
A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
por: Fronik, Philipp, et al.
Publicado: (2022) -
Structure–Activity
Relationships of Triple-Action
Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating
Ligands
por: Fronik, Philipp, et al.
Publicado: (2021)